5th Targeted Radiopharmaceuticals Summit US

Memo

Maximizing the Potential of Radiopharmaceuticals through Novel Targets, Expanded Isotopes and Supply, and Enhanced Dosimetry to Drive Efficacious Therapies From Bench to Approval.Radiopharmaceuticals are no longer an emerging promise, they are becoming a defining force in oncology. Once considered a niche modality, targeted radiopharmaceutical therapies are rapidly moving into the spotlight as one of the most promising approaches for precision cancer treatment. With major pharmaceutical companies investing heavily, pipelines expanding at pace, and clinical successes demonstrating the power of targeted radiation delivery, the field is transitioning from early validation to scale.Momentum across the sector is undeniable. Breakthrough therapies continue to advance through the clinic, alpha-emitting isotopes are unlocking new possibilities for highly potent tumour targeting, and the theranostic paradigm is redefining how patients are diagnosed and treated. As more assets progress into late-stage trials and combination strategies gain traction, radiopharmaceuticals are positioned to play a central role in the next generation of oncology therapeutics.Yet with this rapid growth comes a unique and complex set of challenges. Unlike traditional drug modalities, radiopharmaceutical development requires a tightly integrated ecosystem spanning isotope production, radiochemistry, manufacturing infrastructure, specialized clinical sites, and regulatory expertise.This is why the 5th Targeted Radiopharmaceuticals Summit US returns in 2026 as the industry's most comprehensive end-to-end meeting dedicated to advancing radioligand therapies from discovery through to commercialization. Taking place July 21–23, 2026 in San Diego, California, the summit will bring together 260+ leaders from across the radiopharmaceutical field, including biopharma innovators, nuclear medicine physicians, radiochemists, isotope suppliers, CDMOs, regulators, and investors, to tackle the scientific, clinical, and operational challenges shaping the field.Over three days of technical discussions, strategic insights, and collaborative networking, attendees will explore the full lifecycle of targeted radiopharmaceutical development, from discovery and preclinical innovation through clinical translation, manufacturing scale-up, and supply chain resilience.Whether you are developing the next generation of radioligand therapies, building isotope production capacity, advancing clinical trials, or supporting the infrastructure needed to bring these therapies to patients, the 5th Targeted Radiopharmaceuticals Summit US is where the community comes together to move the field forward. Join the experts shaping the future of targeted radioligand therapy and help define the next chapter of precision oncology.URLs:Tickets: https://go.evvnt.com/3537115-2?pid=5569Brochure: https://go.evvnt.com/3537115-3?pid=5569Date and Time: On Tuesday July 21, 2026 at 8:00 am to Thursday July 23, 2026 at 6:00 pmVenue details: San Diego Marriott La Jolla, 4240 La Jolla Village Drive, La Jolla, California, 92037, United StatesPrices:Drug Developer Pricing - Full Package Conference + Focus Day: USD 4497.00,Drug Developer Pricing - Full Package Conference + Workshop Day: USD 4497.00,Drug Developer Pricing - Conference Only: USD 3199.00,Academic Pricing - Full Package Conference + Focus Day: USD 3897.00,Academic Pricing - Full Package Conference + Workshop Day: USD 3897.00,Academic Pricing - Conference Only: USD 2799.00,Service Provider Pricing - Full Package Conference + Focus Day: USD 5397.00,Service Provider Pricing - Full Package Conference + Workshop Day: USD 5397.00,Service Provider Pricing - Conference Only: USD 3899.00Speakers: Ammar Chaudhry, Global Clinical Head, Radiology and Theranostics, AstraZeneca, Ankur Nagaraja, Clinical Lead for RLT Early Development, Novartis AG, Emily Lu, Senior Clinical Supply Chain Planner, Eli Lilly and Co., Liane Pinto, Director - Clinical Development Medical and RLT Prostate Cancer, Novartis AG, Malini Iyer, Associate Director, AstraZeneca, Marsela Braunstein, Director, Radioconjugates, AstraZeneca, Alexander Schinagl, Co-Founder and Chief Technology Officer, OncoOne, Alison Armour, Chief Medical Officer, CURADH Pharmaceuticals, Ben Hickey, President, Rayzebio, Ben Pais, Chief Medical Officer, Nuclidium, Benjamin Titz, Co-Founder and Chief Executive Officer, Alkyon Therapeutics, Caitlyn Miller, Co-Founder and Chief Executive Officer, TwoStep Therapeutics, Cheryl Maley, Chief Executive Officer, Starpharma Ltd., Chris Pak, CEO, Molecular Targeting Technologies, Christopher Adams, Chief Executive Officer, Andarix Pharmaceuticals., Dan Stevens, Chief Medical Officer, Blue Earth Therapeutics Ltd., Dirk Pleimes, CEO, PentixaPharm GmbH, Jessica Guarnaschelli, Independent Consultant, CURADH Pharmaceuticals, John Babich, President and Chief Scientific Officer, Ratio Therapeutics, Inc., Jose Zayas, Quality Assurance and Regulatory Affairs and Radiopharmaceuticals Chemistry, manufacturing and controls Consultant, Zaycor Industries Corp., Julian Rees, Co-Founder and Chief Executive Officer, HOPO Therapeutics, Kawa Chiu, Chief Technical Officer, Abdera Therapeutics, Kyle Hoffmann, Director - Manufacturing Operations and Co-Founder, Juniper Biosciences, Michael Groaning, Chief Scientific Officer, Soricimed Biopharma Inc., Michel Afargan, Chief Scientific Officer, Head Drug Developments and Radiopharmaceutical Strategies, Starget Pharma, Munir Ghesani, Director and Chief Medical Officer, United Theranostics, Olga Issakova, Chief Operating Officer, Tailor Therapeutics, Phillip Davis, Chief Executive Officer, Ex-FDA, Ramzi Amri, Chief Financial Officer, Oncoinvent AS, Riccardo Canevari, Chief Executive Officer, RadioPharm Theranostics, Rich Messmann, Chief Medical Officer, Convergent Therapeutics, Inc, THOMAS TULIP, Principal, RadioPharm OGs, Akshay Chellappa, Vice President, Global Business Development, Telix Pharmaceuticals, Alessandro Mascioni, Director, Targeting Technology Research, Telix Pharmaceuticals, Alex Mandel, Director, Abdera Therapeutics, Aruna Korde, Radiopharmaceutical Scientist International, Atomic Energy Agency, Caitlyn Harvey, Vice President, Head of CMC, Convergent Therapeutics, Inc, Chad Watkins, General Manager - Isotope Strategy, Telix Pharmaceuticals, Dhiren Patel, Vice President - Clinical Development, Actinium Pharmaceuticals, Guido Würth, Head of Corporate Development Radiopharma, Affibody AB, Kemp Dolliver, Director - Research and Senior Analyst, Brookline Capital Markets, Kirstin Zettlitz, Target Biology Lead, Sego Therapeutics, Lauren Creeden, Head of Clinical CMC Execution, Clarity, Melissa Rodnick, Program manager, Sirtex Medical Limited, Patrick Williams, Senior Director - Human Resource and Talent Acquisition, Mariana Oncology, S. Sakura Minami, Vice President, Translational Medicine and Nonclinical Development, Iron Fist Therapeutics, Yusuke Kohno, Head of Supply Chain Development, Alpha Fusion Inc., Brian Zeglis, Associate Professor, Hunter College of City University, David Mankoff, Professor of Radiology, University of Pennsylvania, David Ulmert, Associate Professor - Residence, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Erik Mittra, Professor OHSU - Oregon Health and Science University, Gunilla Jacobson, Director - Cyclotron, Translational Medicine, DeSimone Lab Technical and Strategic, Stanford University, Mark Sellmyer, Assistant Professor, University of Pennsylvania, Michael Evans, Professor, University of California, San Francisco, Michael Nickels, Associate Professor - Radiology, Washington University School of Medicine in St. Louis, Scott Tagawa, Professor Weill, Cornell Medicine, Estelle Ricoux, Co-Founder and Strategy Director, Design, FIRM, Isabella Pepe, Researcher, Beacon, Kostja Paschalidis, Co-founder, Systems and Logistics, FIRM, Molly McGaughan, Co-Founder, FIRM